DMAC
DiaMedica Therapeutics Inc

1,562
Mkt Cap
$449.43M
Volume
28,831.00
52W High
$9.23
52W Low
$3.19
PE Ratio
-12.03
DMAC Fundamentals
Price
$8.91
Prev Close
$8.63
Open
$8.70
50D MA
$7.02
Beta
1.16
Avg. Volume
524,348.21
EPS (Annual)
-$0.605
P/B
8.71
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) has earned an average rating of "Moderate Buy" from the seven ratings firms that are currently covering the firm, Marketbeat.com reports...
MarketBeat·11d ago
News Placeholder
More News
News Placeholder
DiaMedica Therapeutics (NASDAQ:DMAC) Lowered to "Sell" Rating by Wall Street Zen
Wall Street Zen downgraded shares of DiaMedica Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·19d ago
News Placeholder
DiaMedica Therapeutics (NASDAQ:DMAC) Issues Earnings Results
DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of...
MarketBeat·22d ago
News Placeholder
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction and acute ischemic stroke...
Business Wire·23d ago
News Placeholder
An Overview of DiaMedica Therapeutics's Earnings
read more...
Benzinga·24d ago
News Placeholder
DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke...
Business Wire·25d ago
News Placeholder
DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its...
Business Wire·29d ago
News Placeholder
DiaMedica Therapeutics, Inc. (DMAC) is a Great Momentum Stock: Should You Buy?
Does DiaMedica Therapeutics, Inc. (DMAC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·3mo ago
News Placeholder
After Golden Cross, DiaMedica Therapeutics, Inc. (DMAC)'s Technical Outlook is Bright
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Zacks·3mo ago
News Placeholder
Wall Street Analysts Believe DiaMedica Therapeutics (DMAC) Could Rally 100.81%: Here's is How to Trade
The mean of analysts' price targets for DiaMedica Therapeutics (DMAC) points to a 100.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·3mo ago

Latest DMAC News

View

Advertisement|Remove ads.

Advertisement|Remove ads.